Cholestan-3β,5α,6β-triol

CAS : 1253-84-5

Ref. 3D-FC76729

Informations sur le produit

• Nom: Cholestan-3β,5α,6β-triol
• Synonymes: (3Beta,5Alpha,6Beta)-Cholestane-3,5,6-Triol, (3Beta,5Alpha,6Beta,8Xi,9Xi,14Xi,17Xi,20Xi)-Cholestane-3,5,6-Triol, (3β,5α,6β)-Cholestane-3,5,6-triol, 3β,5α,6β-Trihydroxycholestane, 3β-Hydroxycholestane-5α,6β-diol, 5-Alpha-Cholestane-3-Beta,5,6-Beta-Triol, 5α,6β-Dihydroxycholestanol, 5α-Cholestane-3β,5,6β-triol, Cholesta-3β,5α,6β-triol, Cholestane-3,5,6-triol, Cholestane-3,5,6-triol, (3β,5α,6β)-, Cholestanetriol, NSC 124751, NSC 18178, Cholestane-3β,5α,6β-triol

Description

Cholestan-3b,5a,6b-triol is a naturally occurring fatty acid that has been shown to inhibit the synthesis of cholesterol and oxysterols in animal studies. It also acts as a receptor agonist for the LDL receptor. This compound is used in clinical trials to assess risk for cerebrotendinous xanthomatosis (CTX), a rare genetic disorder characterized by high levels of cholesterol and fatty acids in the brain and spinal cord. Cholestan-3b,5a,6b-triol is being studied as a potential treatment for atherosclerosis. The drug inhibits the uptake of cholesterol from macrophages and reduces the accumulation of atherosclerotic lesions in mouse models. Cholestan-3b,5a,6b-triol may be useful for treating patients with diabetes because it blocks the synthesis of fatty acids that can lead to diabetic complications such as retinopathy and nephropathy.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 420.67 g/mol
• Formule: C₂₇H₄₈O₃
• Degré de pureté: Min. 95%
• Couleur/Forme: Powder
• InChI: InChI=1S/C27H48O3/c1-17(2)7-6-8-18(3)21-9-10-22-20-15-24(29)27(30)16-19(28)11-14-26(27,5)23(20)12-13-25(21,22)4/h17-24,28-30H,6-16H2,1-5H3/t18-,19+,20+,21-,22+,23+,24-,25-,26-,27+/m1/s1
• Code InChI: InChIKey=YMMFNKXZULYSOQ-RUXQDQFYSA-N
• SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@@H](O)[C@@]4(O)C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C